Zolgensma (onasemnogene abeparvovec-xioi), a new gene therapy drug that attracted attention due to its high price of nearly 2 billion won per single shot, is soon to be approved in Korea.

As a spinal muscular atrophy gene therapy, Zolgensma is also called a ‘one-shot treatment’ as only a single dose is required during a patient’s lifetime. As the drug is about to be approved, whether the drug will be allowed reimbursement is expected to be the key issue.

On the 26th, industry sources said that the Ministry of Food and Drug Safety (MFDS) completed the safety and efficacy review for Zolgensma. The results are expected to be announced soon.

Zolgensma was designated as an o